NASDAQ: VERVVerve Therapeutics Inc Stock
$6.22-0.36 (-5.47%)
Updated Apr 25, 2024
VERV Price
$6.22
Fair Value Price
$1.28
Market Cap
$520.11M
52 Week Low
$6.05
52 Week High
$21.42
P/E
-1.99x
P/B
0.87x
P/S
76.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.76M
Earnings
-$200.07M
Gross Margin
100%
Operating Margin
-1,699.21%
Profit Margin
-1,701.5%
Debt to Equity
0.26
Operating Cash Flow
-$150M
Beta
2.1
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VERV Overview
Verve Therapeutics Incorporated developing a novel approach to the care of cardiovascular disease - transforming treatment from chronic management to single-course gene editing medicines. Verve's lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient's risk for cardiovascular disease. Verve Therapeutics was incorporated in 2018 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VERV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VERV ($6.22) is overvalued by 385.87% relative to our estimate of its Fair Value price of $1.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VERV ($6.22) is not significantly undervalued (385.87%) relative to our estimate of its Fair Value price of $1.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VERV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VERV due diligence checks available for Premium users.
Be the first to know about important VERV news, forecast changes, insider trades & much more!
VERV News
Valuation
VERV fair value
Fair Value of VERV stock based on Discounted Cash Flow (DCF)
Price
$6.22
Fair Value
$1.28
Overvalued by
385.87%
VERV ($6.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VERV ($6.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VERV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VERV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.99x
Industry
15.41x
Market
40.97x
VERV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.87x
Industry
5.8x
VERV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VERV's financial health
Profit margin
Revenue
$5.1M
Net Income
-$48.4M
Profit Margin
-940%
VERV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VERV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$752.7M
Liabilities
$153.2M
Debt to equity
0.26
VERV's short-term assets ($637.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERV's short-term assets ($637.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$40.7M
Investing
-$8.9M
Financing
$177.4M
VERV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VERV vs Biotech Stocks
Verve Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.